# Efficacy and Safety of Trastuzumab Biosimilar (Herzuma®) Plus Treatment of Physician's Choice (TPC) in Patients With HER-2 Positive Metastatic Breast Cancer

> **NCT03755141** · PHASE2 · COMPLETED · sponsor: **National Cancer Center, Korea** · enrollment: 109 (actual)

## Conditions studied

- HER2-positive Breast Cancer
- Metastatic Breast Cancer

## Interventions

- **DRUG:** Herzuma

## Key facts

- **NCT ID:** NCT03755141
- **Lead sponsor:** National Cancer Center, Korea
- **Sponsor class:** OTHER_GOV
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2018-12-15
- **Primary completion:** 2021-08-24
- **Final completion:** 2022-06-30
- **Target enrollment:** 109 (ACTUAL)
- **Last updated:** 2025-07-22


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03755141

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03755141, "Efficacy and Safety of Trastuzumab Biosimilar (Herzuma®) Plus Treatment of Physician's Choice (TPC) in Patients With HER-2 Positive Metastatic Breast Cancer". Retrieved via AI Analytics 2026-05-23 from https://api.ai-analytics.org/clinical/NCT03755141. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*